Esco Lifesciences, a Singapore-based manufacturer and service provider of laboratory, biopharma equipment, and IVF medical devices, has acquired its distributor, Esco Korea Micro through a newly formed subsidiary, Esco Lifesciences Korea (Esco Korea).
Esco Korea began operations on 1 October 2024.
This strategic move aims to strengthen Esco Lifesciences’ distribution capabilities by establishing direct sales and service teams to meet the demands of the growing biopharma, research, and clinical markets in South Korea.
Esco Korea began operations on 1 October 2024
By consolidating resources, the acquisition is expected to improve operational efficiency and support expansion in the region.
Esco Lifesciences also plans to leverage this acquisition to advance digital transformation within Esco Lifesciences Korea.
This includes streamlining accounting management, customer relationship management, and other operational areas.
With the acquisition of Esco Korea Micro, we are taking a big step toward enhancing our footprint in the region
Additionally, human capital development will be a focus, with plans to provide training to ensure employees are equipped to adapt to the company’s digitalisation efforts.
Chief Executive Officer of Esco Lifesciences, XQ Lin, said: "With the acquisition of Esco Korea Micro, we are taking a big step toward enhancing our footprint in the region. This strategic move also accelerates our efforts in digital transformation, allowing us to operate more efficiently while expanding our impact."
"We are committed to fostering innovation and growth, empowering our teams, and delivering even greater value to our customers as we shape the future of life sciences together," Lin concluded.
